| 31 | 0 | 57 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：探讨β-榄香烯联合洛铂对肝癌HepG-2细胞生物学行为的影响。方法：用不同浓度β-榄香烯（β-elemene）联合洛铂（Lobaplatin）处理HepG-2细胞，设立阴性对照组、阳性对照组、实验组1、实验组2和实验组3。应用CCK-8法检测细胞存活率，划痕实验和Transwell实验检测细胞迁移和侵袭能力。细胞凋亡率通过Annexin V-FITC/PI双染色流式细胞术定量分析。结果：β-榄香烯能够增强洛铂抑制HepG-2细胞的迁移、侵袭能力（P<0.0001），且其抑制作用随着β-榄香烯浓度的升高而增强。β-榄香烯还能够增强洛铂诱导的HepG-2细胞凋亡，在经不同组别（阴性对照组：0μg/ml β-榄香烯，0μg/ml洛铂；阳性对照组：0μg/ml β-榄香烯，5μg/ml洛铂；实验组1:50μg/ml β-榄香烯，5μg/ml洛铂；实验组2:100μg/ml β-榄香烯，5μg/ml洛铂；实验组3:200μg/ml β-榄香烯，5μg/ml洛铂）药物处理24 h后，细胞凋亡率分别为（8.29±0.54）%、（17.84±1.24）%、（21.61±1.49）%、（31.26±3.54）%、（38.05±0.25）%，差异有统计学意义（P<0.0001）。结论：β-榄香烯能够增强洛铂对肝癌HepG-2细胞增殖、迁移和侵袭的抑制作用，促进其凋亡，从而提高肝癌HepG-2细胞对洛铂的敏感性。
Abstract：Objective:To explore how the combination of β-elemene and lobaplatin influences the biological characteristics of HepG-2 cells in hepatocellular carcinoma.Methods:HepG-2 cells were subjected to treatment with varying concentrations of β-elemene in conjunction with lobaplatin. Control groups included a blank control and a lobaplatin-only control group. To evaluate cell survival rates,the CCK-8 assay was utilized. The assessment of migration and invasion capabilities was conducted using scrape and Transwell assays. Apoptosis rates were deter mined by double staining with Annexin V-FITC and propidium iodide(PI).Results:At all tested concentrations,β-elemene synergistically increased lobaplatin's anti-migratory and anti-invasive activities against HepG-2 cells(P<0.0001),with the inhibitory effects strengthening in a concentration-dependent fashion. β-elemene can also enhance the apoptosis of HepG-2 cells induced by lobaplatin,and the experimental results have shown that after different groups of different drugs(Negative control group:0 μg/ml β-elemene,0 μg/ml Lobaplatin;Positive control group:0 μg/ml β-elemene,5μg/ml Lobaplatin;Experimental group 1:50 μg/ml β-elemene,5 μg/ml Lobaplatin;Experimental group 2:100 μg/mlβ-elemene,5 μg/ml Lobaplatin;Experimental group 3:200 μg/ml β-elemene,5 μg/ml Lobaplatin)for 24 h,the apoptosis rates were(8.29±0.54)%,(17.84±1.24)%,(21.61±1.49)%,(31.26±3.54)% and(38.05±0.25)%,respectively,with statistical difference between groups(P<0.0001).Conclusion:β-elemene has the capacity to strengthen the ability of lobaplatin to inhibit the proliferation,migration,and invasion of HepG-2 cells. Additionally,it promotes apoptosis in these cells and enhances their sensitivity to lobaplatin treatment.
[1] Chen P,Yuan P,Chen B,et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma:a systematic review and metaanalysis[J]. Clin Res Hepatol Gastroenterol,2017,41(1):75-85.
[2] Singal AG,Kanwal FL,lovet JM. Global trends in hepatocellular carcinoma epidemiology:implications for screening,prevention and therapy[J]. Nat Rev Clin Oncol,2023,20(12):864-884.
[3] Dhanasekaran R,Limaye A,Cabrera R. Hepatocellular carcinoma:current trends in worldwide epidemiology,risk factors,diagnosis,and therapeutics[J]. Hepat Med,2012,4:19-37.
[4] Bruix J,Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma[J]. Hepatology,2002,35(3):519-524.
[5] Galun D,Basaric D,Zuvela M,et al. Hepatocellular carcinoma:From clinical practice to evidence-based treatment protocols[J]. World J Hepatol,2015,7(20):2274-2291.
[6] Lawson A,Kamarajah SK,Parente A,et al. Outcomes of transarterial embolisation(TAE)vs. transarterial chemoembolisation(TACE)for hepatocellular carcinoma:a systematic review and meta-analysis[J].Cancers(Basel),2023,15(12):3166.
[7] Peng S,Yang QX,Zhang T,et al. Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma[J]. Asian Pac J Cancer Prev,2014,15(13):5155-5160.
[8] He H,Shang XY,Liu WW,et al. Triterpenes from the fruit of Camptotheca acu minata suppress human hepatocellular carcinoma cell proliferation through apoptosis induction[J]. Nat Prod Res,2019,33(24):3527-3532.
[9] Luo P,An Y,He J,et al. Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkinmediated mitophagy in hepatocellular carcinoma[J].Cancer Lett,2024,587:216621.
[10] Feng Y,An Q,Zhao Z,et al. Beta-elemene:a phytochemical with promise as a drug candidate for tumor therapy and adjuvant tumor therapy[J]. Biomed Pharmacother,2024,172:116266.
[11] Wang J,Qian C,Chen Y,et al. β-elemene alleviates hyperglycemia-induced cardiac inflammation and remodeling by inhibiting the JAK/STAT3-NF-κB pathway[J]. Phytomedicine,2023,119:154987.
[12]刘梅，郭小红，孙全，等.温郁金的化学成分和药理作用研究进展[J].现代药物与临床，2021,36(1):204-208.
[13] Zhu TZ,Li XM,Luo LH,et al. β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells[J]. Mol Med Rep,2014,10(2):1122-1128.
[14] Zhai B,Zeng Y,Zeng Z,et al. Drug delivery systems for elemene,its main active ingredient β-elemene,and its derivatives in cancer therapy[J]. Int J Nanomedicine,2018,13:6279-6296.
[15] Yao Y,Chen J,Jiao D,et al. Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a meta-analysis[J]. Medicine(Baltimore),2019,98(44):e17813.
[16] McKeage MJ. Lobaplatin:a new antitumour platinum drug[J]. Expert Opin Investig Drugs,2001,10(1):119-128.
[17] Li X,Ran L,Fang W,et al. Lobaplatin arrests cell cycle progression,induces apoptosis and alters the proteome in human cervical cancer cell Line CaSki[J]. Biomed Pharmacother,2014,68(3):291-297.
[18]王芮，王义俊.两种评估方法探究洛铂对老年肿瘤患者肾功能的影响[J].中国药师，2022,25(9):1593-1597.
[19] Lv Y,Xu A,Wang N,et al. Retrospective study of TACE in the treatment of lobaplatin-induced thrombocytopenia in primary hepatocellular carcinoma[J]. J Buon,2019,24(6):2385-2393.
[20] Martin SP,Fako V,Dang H,et al. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2020,39(1):99.
[21] Yang C,Luo YG,Yang HC,et al. Effects of early TACE refractoriness on survival in patients with hepatocellular carcinoma:a real-world study[J]. J Hepatocell Carcinoma,2022,9:621-631.
[22]孙清秀，蒲凤华. β-榄香烯治疗结直肠癌作用机制研究进展[J].现代药物与临床，2024,39(5):1354-1359.
[23]王君钰，朱少平，李林均.榄香烯注射液对人肝癌细胞系HepG2体外增殖的影响[J].武汉大学学报（医学版），2019,40(5):734-736.
[24]翟秉涛，田欢，孙静，等.榄香烯及β-榄香烯抗肿瘤靶向药物递送系统的研究进展[J].中成药，2023,45(6):1921-1928.
[25]李丹，杨英，郝志晔.中药提取物榄香烯治疗原发性肝癌的研究进展[J].中西医结合肝病杂志，2023,33(2):185-188.
[26] Li P,Li Y,Ma L. Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis[J]. Pharmacol Res Perspect,2021,9(4):e815.
[27]杨军，杨帆，缪娴，等. β-榄香烯调节HULC表达对肝癌细胞恶性生物学行为的影响[J].临床肿瘤学杂志，2023,28(12):980-985.
[28]王子俊，苏永强，武二伟，等.榄香烯注射液联合TP化疗同步放疗治疗局部晚期食管癌患者的效果和安全性[J].内科，2023,18(2):131-135.
[29]杨子媚，刘蒙，林尚明，等.经肝动脉灌注榄香烯乳剂联合经肝动脉化疗栓塞术治疗原发性肝癌疗效及安全性的Meta分析[J].广州中医药大学学报，2022,39(11):2701-2708.
[30]张丽娟，闫向勇，燕忠生.榄香烯联合经动脉化疗栓塞治疗中晚期肝癌的Meta分析[J].中医临床研究，2022,14(31):73-76.
基本信息:
DOI：
中图分类号:R735.7
引用信息:
[1]卢如意,段光峰,张韬等.β-榄香烯联合洛铂对肝癌HepG-2细胞增殖、迁移、侵袭及凋亡的影响[J].广州医科大学学报,2025,53(03):1-7.
基金信息:
广州市中医药和中西医结合科技项目(20212A011025,20222A010048)